Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China - The Next Promised Land For Korean Biosimilars?

Executive Summary

Biosimilar specialists Celltrion and Samsung Bioepis are poised to start competing in China, which they see as another promising market for their biosimilars amid the Chinese government's increasing policy support for biologics and generics, and rising competition elsewhere. Part of their tailored entry approach includes striking deals with local partners.

Advertisement

Related Content

Chinese Biosimilar Boom Is Heralded By First Approval
Biosimilar Boom in China Heralded By First Approval
Nine Catalysts For China Biopharma In 2019
Asia Deal Watch: Boost For Esperion's Cholesterol Candidate As Daiichi Brought On Board
Better Together: New Deal Adds Weight To China Biosimilar/Biobetter Swap
Biosimilar Tipping Point: Five Questions For Henlius CEO
Celltrion Gets Go-Ahead For Remsima Trials In China, Mulls JV

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124644

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel